| Abstract P244 – Table 1. Demographic profile, clinical characteristics and outcomes of COVID‐19 in HIV‐infected patients with tenofovir and non‐tenofovir based baseline ART. Values are numbers (percentages) unless otherwise stated. | |||
|---|---|---|---|
| Tenofovir (TDF/TAF) cohort (n = 929) | Non‐tenofovir cohort (n = 228) | p‐value | |
| Male sex | 612 (65.8%) | 145 (63%) | 0.091 |
| Age, years (median, IQR) | 43 (36 to 51) | 50 (40 to 57) | 0.011 |
| Comorbidities | 352 (37.8%) | 115 (59.4%) | 0.001 |
| Virological suppression | 758 (81.5%) | 179 (78.5%) | 1.000 |
| CD4 T‐cell count cel/uL (median, IQR) | 598 (434 to 800) | 656.5 (472.5 to 824) | 0.824 |
| Symptomatic COVID‐19 (n, %) | 891 (95.9%) | 221 (96.9%) | 0.509 |
| Radiographic abnormalities (n/N, %) | 85/197 (45.1%) | 24/59 (40.6%) | 1.000 |
| Hospitalisation | 146 (15.7%) | 41 (17.9%) | 0.119 |
| Oxygen therapy | 83 (8.94%) | 31 (13.5%) | 0.040 |
| COVID‐19 therapy | 105 (11.3%) | 30 (13.1%) | 0.618 |
| Mortality | 8 (0.86%) | 5 (2.1%) | 1.000 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.